Literature DB >> 6640524

Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes.

A Mazumder, M Rosenstein, S A Rosenberg.   

Abstract

This paper demonstrates that lectin-activated lymphocytes of selected mouse strains can lyse fresh autologous or allogeneic tumor cells but not the fresh normal cells tested in short-term 51Cr release assays. Murine splenocytes, incubated with concanavalin A for 3 days, lysed tumor cells from fresh syngeneic P815 mastocytoma, 102 methylcholanthrene sarcoma, and FBL3 lymphoma; fresh allogeneic 3LL lung carcinoma and MethA sarcoma; and tissue-cultured YAK cells in 18-hr51Cr release assays. Natural killer cells in fresh splenocyte preparations only lysed tissue-cultured YAK cells and not the other targets. Syngeneic and allogeneic lymphoblasts, lung, or liver cells were not lysed by the concanavalin A-activated killer (CAK) cells. The induction of cytotoxicity by concanavalin A incubation was abrogated by alpha-methylmannoside in the 3-day incubation, but not in cytotoxicity assay. Radiosensitive cells and adherent cells were necessary for the generation of CAK cells. The CAK effectors themselves were radioresistant, nonadherent, and mostly Thy 1+ and Ly 2+. The CAK phenomenon may be mediated by lymphokine production by an Ly 1+ cell, since depletion of Ly 1+ cells prior to activation abrogates CAK induction, and the ability of numerous mouse strains (and nude mice) to generate CAK cells correlated with their ability to produce Interleukin 2. The biological and therapeutic role of these cells is currently being investigated in murine syngeneic primary and metastatic tumor models.

Entities:  

Mesh:

Year:  1983        PMID: 6640524

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations.

Authors:  R Agah; H Shau; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 2.  The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.

Authors:  S A Rosenberg
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

3.  Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.

Authors:  R R Salup; R H Wiltrout
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.